NYSE · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Actinium Pharmaceuticals, Inc. ATNM
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$90,000
EPS · FY25
$-1.09
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-167.0%
Net margin · FY25
-37652.2%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 90,000.00
Revenue, FY2025 · full 19-year series below
Revenue
Net income
The company lost 37652 cents on every revenue dollar this year.
Per share
USD -1.09
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-167.0%
Return on equity, FY2025
ROE
Operating margin-40274.4%
Net margin-37652.2%
Return on assets-52.7%
Each USD of equity lost 167 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−55.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.03B
Shares outstanding, FY2025
Change, 5 years+77.9%
Change, 10 years—
The share count grew 78% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 51.8M
total assets, end of FY2025
Total assetsUSD 51.8M
EquityUSD 7.8M
CashUSD 48.0M
Current ratio6.20×
Equity funds 15% of total assets.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
0.0
·
0.0
0.0
0.0
·
·
·
·
·
·
·
·
·
0.0
0.0
·
·
·
Operating income $B
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
EBITDA $B
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
·
·
Income tax $B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
0.0
−0.0
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−1.09
−1.27
−1.83
−1.37
−1.20
−1.83
−4.40
−0.22
−0.40
−0.50
−0.55
−0.90
−0.47
−7.58
−4.30
0.01
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−167.0
−110.6
−94.9
−47.2
−36.7
−66.4
−303.0
−210.4
−167.9
−121.7
−209.7
·
·
−782.3
−495.3
−75.1
−136.9
−146.2
−162.4
Shares out B
0.03
0.03
0.03
0.03
0.02
0.02
0.01
0.12
0.08
0.06
0.04
0.03
0.02
0.02
0.01
0.01
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
49 of 49
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed